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ABSTRACT
Objective: To determine associations between cerebral microbleed (CMB) burden with recurrent
ischemic stroke (IS) and intracerebral hemorrhage (ICH) risk after IS or TIA.
Methods:We identified prospective studies of patients with IS or TIA that investigated CMBs and
stroke (ICH and IS) risk during $3 months follow-up. Authors provided aggregate summary-level
data on stroke outcomes, with CMBs categorized according to burden (single, 2–4, and$5CMBs)
and distribution. We calculated absolute event rates and pooled risk ratios (RR) using random-
effects meta-analysis.
Results:We included 5,068 patients from 15 studies. There were 115/1,284 (9.6%) recurrent IS
events in patients with CMBs vs 212/3,781 (5.6%) in patients without CMBs (pooled RR 1.8 for
CMBs vs no CMBs; 95% confidence interval [CI] 1.4–2.5). There were 49/1,142 (4.3%) ICH
events in those with CMBs vs 17/2,912 (0.58%) in those without CMBs (pooled RR 6.3 for CMBs
vs no CMBs; 95%CI 3.5–11.4). Increasing CMB burden increased the risk of IS (pooled RR [95%
CI] 1.8 [1.0–3.1], 2.4 [1.3–4.4], and 2.7 [1.5–4.9] for 1 CMB, 2–4 CMBs, and $5 CMBs, respec-
tively) and ICH (pooled RR [95% CI] 4.6 [1.9–10.7], 5.6 [2.4–13.3], and 14.1 [6.9–29.0] for 1
CMB, 2–4 CMBs, and $5 CMBs, respectively).
Conclusions: CMBs are associated with increased stroke risk after IS or TIA. With increasing CMB
burden (compared to no CMBs), the risk of ICH increasesmore steeply than that of IS. However, IS
absolute event rates remain higher than ICH absolute event rates in all CMB burden categories.
Neurology® 2016;87:1501–1510
GLOSSARY
CAA 5 cerebral amyloid angiopathy; CI5 confidence interval; CMB 5 cerebral microbleed; ICH 5 intracerebral hemorrhage;
IS 5 ischemic stroke; SWI 5 susceptibility-weighted imaging.
Cerebral microbleeds (CMBs) are radiologically defined small round or ovoid regions of signal
loss seen on paramagnetic MRI sequences.1 In the limited available pathologic correlation
studies, CMBs mostly correspond to hemosiderin-laden macrophages close to vessels affected
by small vessel disease.2–5 It is thus inferred that CMBs are a marker of direct extravasation of
erythrocytes from arterioles and capillaries damaged by bleeding-prone arteriopathies. An arte-
riopathy associated with systemic arterial hypertension and pathologic changes in small perfo-
rating arteries of the deep gray and white matter causes CMBs in deep (basal ganglia) as well as
lobar regions. In Western (Caucasian) people with intracerebral hemorrhage (ICH), CMBs in
From the Stroke Research Centre (D.W., A.C., S.G., P.R., D.J.W.), Department of Brain Repair and Rehabilitation, UCL Institute of
Neurology and The National Hospital for Neurology and Neurosurgery; Department of Statistical Science (G.A.) and Biomedical Research
Centre (Z.V.F.), UCL, London, UK; Department of Neurosurgery (T.I.), Kushiro City General Hospital, Hokkaido, Japan; Department of
Neurology (F.F.), University Hospital Würzburg, Germany; Department of Neurology (H.N.), Suiseikai Kajikawa Hospital, Hiroshima, Japan;
Department of Neurology (S.H.), University of Heidelberg, Germany; Department of Stroke Medicine (R.V.), Division of Brain Sciences,
Imperial College London; Nuffield Department of Clinical Neurosciences (P.M.R.), John Radcliffe Hospital, University of Oxford, UK;
Department of Neurology (V.I.H.K.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; Department of Neurology (V.T.), Austin
Health and Melbourne Brain Center, University of Melbourne, Australia; Department of Neurology (Y.-S.L.), Seoul National University
Boramae Medical Center; Department of Neurology (Y.D.K.), Yonsei University College of Medicine, Seoul, Korea; Department of Neurology
(Y.H.), Peking University First Hospital, Beijing, China; Division of Neurology (K.S.W.), Department of Medicine & Therapeutics, The
Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; and Lysholm Department of Neuroradiology (H.R.J.),
National Hospital for Neurology and Neurosurgery, London, UK.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was paid by Wellcome Trust.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited.
© 2016 American Academy of Neurology 1501
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
a strictly lobar distribution are highly specific
for cerebral amyloid angiopathy (CAA), which
causes progressive deposition of b-amyloid in
small cortical and leptomeningeal arterial
walls,6 though this pattern may not be so spe-
cific in Eastern (Asian) people7 and in those
without ICH.8
Multiple prospective studies in ischemic
stroke (IS) cohorts have shown that CMBs
are associated with subsequent ICH risk.9,10
However, CMBs are also associated with
increased subsequent IS risk.11–14 Indeed, sug-
gested ischemic mechanisms for CMBs
include ischemia-mediated iron store release
by oligodendrocytes,15 phagocytosis of red cell
microemboli into the perivascular space
(termed angiophagy),16 or hemorrhagic trans-
formation of small microinfarcts.17 Indeed, in
a recent community study, after adjusting for
cardiovascular risk factors, CMBs were found
to be associated with lacunes and white matter
volume progression.18 Few data are available
on how CMB burden affects the balance of
ICH and IS risk in different populations. In
CAA cohorts, an increasing number of CMBs
is associated with an increased risk of ICH,
suggesting a relationship between CMB num-
ber and the severity of bleeding-prone arterio-
pathy.19 Whether an increasing number of
CMBs is also associated with an increased risk
of ICH in IS and TIA cohorts remains uncer-
tain. If increasing CMB burden shifts the bal-
ance of risk toward ICH rather than IS, this
could have major clinical relevance for antith-
rombotic risk-benefit decisions after IS and
TIA. Our previous meta-analysis of 10 pro-
spective studies including 3,067 patients with
IS or TIA found that CMB presence is associ-
ated with a higher risk of ICH than IS20 (the
odds ratio was 8.53 for ICH and 1.55 for IS),
but was not able to address the key clinical
question of how the number (burden) of
CMBs influences ICH and IS risk.
We therefore performed a pooled analysis of
aggregate summary data, including CMB bur-
den and distribution, to investigate the risk of
subsequent IS and ICH in individuals who have
had an IS or TIA. We tested the following
hypotheses: (1) CMB presence is associated
with an increased risk of stroke (ICH . IS);
and (2) as CMB burden increases (due to amore
severe bleeding-prone arteriopathy), the risk of
ICH increases more steeply than the risk of IS.
METHODS We searched Medline and Embase from 1996 (the
year CMBs were first reported) through to April 2015. Our
search strategy was as follows:
1. “Cerebral microbleed*” or CMB or “cerebral microh?emorr*”
or “brain microbleed*” or “brain microh?emorr*”
2. Stroke or “isch?emic stroke” or TIA or “intrac* adj2 h?
emorrhag*” or ICH
3. 1 and 2
We included published and unpublished studies fulfilling the
following criteria: (1) performed paramagnetic-sensitive MRI se-
quences to detect CMBs at baseline; (2) assessed CMBs at base-
line and associations with IS or ICH as primary or secondary
outcomes; (3) had a prospective study design with at least 3
months of follow-up; and (4) fulfilled at least 4 of 6 predefined
quality indicators. We excluded cross-sectional studies and case
series. Two clinical research fellows (A.C. and D.W.) reviewed
each study for eligibility.
Data extraction. We contacted all authors to provide data
on study population, size, patient-year follow-up, and
antithrombotic treatment. We obtained data on outcome
events of symptomatic IS and ICH, with baseline CMB number
categories as follows: CMB present, 1 CMB, .1 CMB, 2–4
CMBs, 5–10 CMBs, .10 CMBs, strictly deep CMBs, strictly
lobar CMBs, and mixed distribution CMBs. We extracted
all demographic, imaging, and follow-up outcome data
from each study.
Quality assessment and reducing the risk of bias. All
included studies were critically appraised against a checklist of 6
key quality indicators (table e-1 at Neurology.org), with
reference to the Strengthening the Reporting of Observational
Studies in Epidemiology statement and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guidelines. The
quality criteria included assessment for bias, and all studies had
a quality score of $4/6.
Statistical methods. We first performed separate random effect
meta-analyses to derive summary estimates of the pooled risk
ratios of ICH and IS for each CMB category vs the reference
category of “no CMBs.” Due to the small number of events in
some studies, the categories 5–10 and .10 were combined, in
line with previous studies of CMB burden and prognosis, which
demonstrated their prognostic relevance for future ICH risk.19
Logistic regression was then used to estimate the increased risk
(odds) of IS/ICH for each additional CMB. First, CMB
categories were converted to a continuous scale by assuming
that patients in the CMB groups 0, 1, 2–4, 5–10, and .10
had, on average, 0, 1, 3, 7.5, and 12.5 CMBs, respectively.
Then, for each study, a logistic regression model was fitted
relating the (log) odds of IS or ICH to the (estimated) number
of CMBs. These (log) odds ratios were then pooled using random
effects meta-analysis.
We calculated the I2 statistic to investigate heterogeneity.
Funnel plots (Begg and Mazumdar) were generated to investigate
publication bias. Finally, where necessary, we undertook meta-
regression of confounding covariates of biological plausibility or
with differences between the studies (average follow-up, age,
hypertension prevalence, demographics, antithrombotic use).
All analyses were performed using STATA 12.0 (StataCorp LP,
College Station, TX).
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Standard protocol approvals, registrations, and patient
consents. Individual studies and data transfer protocols were
approved by local ethics committees. No additional ethical
approval was required for this meta-analysis.
RESULTS Fifteen studies met our inclusion criteria
(12 published and 3 unpublished) including 5,068
patients9,11–14,21–27 (figure 1). The patient and data
characteristics of each study are shown in tables e-2
and e-3. Twelve of the 15 studies provided data on
CMBs at the time of the initial IS/TIA fully stratified
into number categories and location. Eight studies
involving 3,111 patients were from predominantly
Eastern (Asian) cohorts; the remainder (1,957 patients)
were predominantlyWestern (Caucasian). Two studies
included strictly TIA patients, 4 included those with
TIA or IS, and 9 included strictly IS patients. The
number of patients with CMBs was 1,284, giving an
overall pooled prevalence of 25.3%. Median follow-up
was 18 months (interquartile range 11–30). Overall,
79% of patients were prescribed antiplatelet agents;
only 15% of patients were prescribed anticoagulants
(mainly from one study with a high proportion
of patients on anticoagulation [87%]).24 CMB
presence was more prevalent, with higher burden,
in the Eastern cohorts compared to Western cohorts
(table e-3).
CMBs and IS risk. The total recurrent IS rate was 327/
5,068 (6.5%). The IS event rate in those with CMBs
was 9% (115/1,284) vs 5.6% (212/3,781) for those
without CMBs; thus, CMBs are associated with an
absolute risk increase of 3.4% for IS. The absolute
risk increase for IS for CMBs vs no CMBs increases
as the CMB burden increases (1.8% for 1 CMB,
4.8% for 2–4 CMBs, and 5.1% for $5 CMBs
[table 1]).
The risk ratios for different CMB burden and dis-
tribution categories on IS are also shown in table 1.
The presence of CMBs (vs no CMBs) was associated
with a pooled risk ratio of recurrent IS of 1.8 (95%
confidence interval [CI] 1.4–2.5) (figure 2). Funnel
plots revealed no evidence of publication bias (Egger
test p 5 0.4). The presence of a single CMB (vs no
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart of study selection
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CMBs) had a pooled risk ratio for IS of 1.8 (95% CI
1.0–3.1). The pooled risk estimates for IS suggest an
increasing trend toward higher IS risk with increas-
ing CMB burden (table 1 and figure 3). Logistic
regression was used to estimate the increase in risk
for each additional CMB; this showed an odds ratio
of 1.10 (95% CI 1.06–1.14) per CMB increase (fig-
ure e-1). The risk estimates for IS for each distribu-
tion category of CMBs (vs no CMBs) ranged from
1.6 (95% CI 1.0–2.7) for strictly deep CMBs to 2.6
(95% CI 1.5–4.3) for mixed CMBs, with overlap-
ping confidence intervals for all groups. Because we
noted statistical heterogeneity among the cohorts for
IS risk (I2 33%, 47%, 68%, and 51%, respectively,
for CMB presence, 1 CMB, 2–4 CMB, and $5
CMB, respectively), each potential confounder (eth-
nicity, average follow-up, age, hypertension preva-
lence, and antithrombotic use) was investigated
separately using meta-regression (table e-4, figure
e-2). We found only weak evidence for a confound-
ing effect of hypertension; as expected, the relative
risk associated with baseline CMBs on future IS risk
(effect size) is attenuated in studies with a higher
prevalence of hypertension.
CMBs and ICH risk. The total ICH rate was 66/5,068
(1.3%). The ICH event rate in those with CMBs was
4.3% (49/1,142) vs 0.5% (17/2,912) for those with-
out CMBs; thus, CMBs confer an absolute risk
increase of 3.8% for ICH. The absolute risk increase
for ICH for CMBs vs no CMBs increases as the CMB
burden increases (1.7% for 1 CMB, 1.8% for 2–4
CMBs, and 8.2% for $5 CMBs [table 1]).
The risk ratios for different CMB burden and dis-
tribution categories on ICH are also shown in table 1.
The presence of CMBs (vs no CMBs) was associated
with a pooled risk ratio of 6.3 for subsequent ICH
(95% CI 3.5–11.4) (figure 2). Four studies were
excluded, as they did not report any ICH outcomes.
Increasing CMB burden was associated with an
increased risk of ICH (pooled risk ratio 4.6 [95%
CI 1.9–10.7], 5.6 [95% CI 2.4–13.3], and 14.1
[95% CI 6.9–29.0] for 1 CMB, 2–4 CMBs, and
$5 CMBs compared to no CMBs, respectively)
(table 1 and figure 4). Logistic regression showed an
odds ratio of 1.29 (95% CI 1.21–1.37) for ICH per
additional CMB (figure e-1). Of the CMB anatomi-
cal distribution categories (strictly lobar, mixed, or
strictly deep), strictly lobar CMBs were associated
with the highest risk of subsequent ICH vs no CMBs
(pooled risk ratio 10.5 [95% CI 4.5–24.3]; table 1).
There was no publication bias within studies (Egger
test p 5 0.98). Meta-regression was not undertaken
because heterogeneity was not detected (I2 was 0%)
for ICH outcomes.
DISCUSSION Our meta-analysis of 15 prospective
studies, including more than 5,000 patients
presenting with IS or TIA, found that the presence
of any CMBs is associated with an approximate
doubling of the risk of IS, but with an
approximately 6-fold increase in the risk of ICH, in
keeping with 2 previous smaller meta-analyses.20,28
Our meta-analysis also builds on these previous
studies and adds new knowledge on ICH risk: first,
we were able to increase our statistical power by
including more ICH outcomes20; second, by
pooling aggregate data, we investigated how
increasing CMB burden affects the balance between
future IS and ICH (including both relative and
absolute risks); and third, we partially adjusted for
confounding factors through meta-regression. Our
most important new finding is that with increasing
CMB burden, the risk of ICH increases more steeply
than that of IS. In patients with$5 CMBs, the risk of
ICH was substantially higher than that of IS (risk
ratio for ICH 14.1 [95% CI 6.7–29.0] vs risk ratio
for IS 2.73 [95% CI 1.5–4.9]). In a complementary
Table 1 Pooled relative risk for recurrent ischemic stroke and intracerebral hemorrhage for different cerebral microbleed (CMB) burden and
distribution (all risk ratios are compared to the reference category of no CMBs)
CMB
distribution, n
Ischemic stroke Intracerebral hemorrhage
Pooled absolute
event rates, n/N (%)
Pooled absolute
risk increase, %
Pooled
RR
Lower
95% CI
Upper
95% CI
Pooled absolute
event rates, n/N (%)
Pooled absolute
risk increase, %
Pooled
RR
Lower
95% CI
Upper
95% CI
CMB presence 115/1,284 (9) 3.4 1.8 1.4 2.5 49/1,142 (4.3) 3.8 6.3 3.5 11.4
1 CMB 31/433 (7.2) 1.8 1.8 1.0 3.1 8/354 (2.3) 1.7 4.6 1.9 10.7
2–4 CMBs 44/433 (10.2) 4.8 2.4 1.3 4.4 9/383 (2.3) 1.8 5.6 2.4 13.3
‡5 CMBs 34/342 (10.5) 5.1 2.7 1.5 4.9 24/274 (8.8) 8.2 14.1 6.9 29.0
Strictly lobar 31/332 (9.3) 3.9 2.0 1.4 2.9 12/332 (3.6) 3.2 10.5 4.5 24.3
Strictly deep 29/437 (6.6) 1.2 1.6 1.0 2.7 6/437 (1.4) 1 3.3 1.3 8.5
Mixed 44/411 (10.7) 5.3 2.6 1.5 4.3 25/411 (6.1) 5.7 11.1 5.5 22.6
Abbreviations: CI 5 confidence interval; n 5 number of events in each subgroup; N 5 total number of patients in each subgroup; RR 5 risk ratio.
1504 Neurology 87 October 4, 2016
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
logistic regression analysis, we showed that each
additional CMB is associated with an increased
odds of 1.3 (95% CI 1.2–1.4) for ICH and 1.1
(95% CI 1.1–1.1) for IS, supporting a steeper
increase in ICH than IS risk with higher CMB
burden. However, the absolute event rate of
Figure 2 Forest plot of the risk of ischemic stroke (IS) and intracerebral hemorrhage (ICH) for presence of any
cerebral microbleeds (CMBs) vs no CMBs
CI 5 confidence interval; RR 5 risk ratio.
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Figure 3 Forest plot of the risk of ischemic stroke (IS) for different burdens of cerebral microbleeds (CMBs) vs
no CMBs
CI 5 confidence interval; RR 5 risk ratio.
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Figure 4 Forest plot of the risk of intracerebral hemorrhage (ICH) for different burdens of cerebral
microbleeds (CMBs) vs no CMBs
CI 5 confidence interval; RR 5 risk ratio.
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recurrent IS was consistently higher than the absolute
event rate of ICH in patients with CMBs and within
all CMB categories, including those with $5 CMBs.
A large number of CMBs (e.g., $5 CMB) might
help identify patients at substantially higher risk of
ICH than of IS. Indeed, for clinicians, the key ques-
tion is what burden of CMBs could tip the balance of
risk towards ICH sufficiently to affect clinical deci-
sions; for example, antithrombotic drug use. Antipla-
telet agents only modestly reduce the absolute risk of
IS in secondary prevention (0.5%–2.5%).29 Our data
show the absolute risk of ICH increases substantially
more than the absolute risk of IS as CMB burden
increases; the effect is most evident with $5 CMBs,
which is associated with an 8.2% absolute risk
increase for ICH vs a 5.1% absolute risk increase
for IS. This raises the possibility that antiplatelet drug
risk-benefit assessment may favor avoiding their use
in those with numerous CMBs (e.g., $5 CMBs).
This could affect a substantial proportion of IS and
TIA patients; of patients with CMBs, the prevalence
of those with$5 CMBs ranged from 12% to 51% in
studies included in this analysis (table e-3) and varied
by ethnicity (mean 17% for Western cohorts and
35% for Eastern cohorts).
A previous meta-analysis suggested that ethnicity
may be an important determinant of the balance of
ICH and IS risks associated with CMBs; an increased
risk for ICH risk was only statistically significant in
Eastern cohorts, while IS risk was only significant in
Western cohorts.20 In the present study, we included
more patients, and using meta-regression found that
ethnicity does not confound the association between
CMB burden and IS or ICH risks. Thus, based on
the current study, CMB burden appears to be
a greater predictor of IS and ICH risk than ethnicity.
Our study has a number of strengths, including
a large sample size from multiple cohorts from differ-
ent countries. We only included those of high quality
using systematic quality indicator assessment. We
included data on CMB burden and distribution,
and adjusted for confounding factors through meta-
regression. Our study thus provides the best currently
available evidence on how CMBs affect IS and ICH
risk after IS or TIA.
Our study also has limitations. Because we
included aggregate summary-level data (rather than
individual patient data), we could not explore the
effect of CMB distribution free from the confound-
ing effect of CMB burden. The mixed CMB cate-
gory has the highest risk of stroke, but by
definition includes only patients with multiple
CMBs; by contrast, the strictly lobar and strictly
deep CMB categories could include patients with
a single CMB. Specifically, we could not fully
investigate the independent risk associated with
strictly lobar CMBs, critical to the diagnosis of
CAA4 with high recurrent ICH risk.19,30 Although
we undertook meta-regression, this can only par-
tially account for confounding and is unlikely to
fully account for variables such as age and hyper-
tension. Our logistic regression assumes an average
CMB count within each category (difficult to esti-
mate in the open-ended $10 CMB category) and
that the log odds of ICH/IS increase linearly with
CMB burden. However, consistent findings from 2
complementary statistical analyses strongly support
the hypothesis that increasing CMB burden in-
creases the risk of ICH more than that of IS. Fur-
ther limitations include the variable study sample
size and follow-up, which may bias our results,
especially regarding ICH, a rare outcome with wide
CIs around risk estimates (which overlap for the
different CMB burden categories). A time to event
analysis may have been a more appropriate statisti-
cal method given the varying follow-up, but this
was not possible with the data available. Imaging
protocols and analysis were similar but not com-
pletely uniform (table e-2); field strength,31 echo
time,32 and optimized paramagnetic sequences33
can all influence CMB detection. However, most
studies were performed at 1.5T with echo times
within a narrow range, making this unlikely to
affect our conclusions. Nevertheless, our results
are only generalizable to patients scanned on
1.5T MRI using gradient recalled echo and may
not be applicable to susceptibility-weighted imag-
ing (SWI) or MRI with a higher field strength. SWI
increases the number of CMBs detected33,34 com-
pared to T2*-weighted images; CMB burden cate-
gories may thus have to be revised for SWI. Finally,
studies used different methods for CMB rating;
standardized rating instruments1,35,36 may improve
the reliability of defining CMB categories, partic-
ularly that of a single CMB.
Although our study provides important new
information, to fully determine how CMBs might
influence antithrombotic decisions, the interaction
between CMBs and antiplatelet agents and antico-
agulants needs to be further addressed in large pro-
spective studies. Although the prevalence of
antithrombotic and anticoagulant use did not
show an association with either ICH or IS outcome
in our meta-regression, the large majority of pa-
tients we included were treated with antiplatelet
agents. Very few patients included in our meta-
analysis were on anticoagulation; more data are
therefore needed on this group, who may be at
highest ICH risk. Ongoing prospective observa-
tional studies addressing this question include
ucl.ac.uk/cromis-237 and clinicaltrials.gov/ct2/
show/NCT02238470. Further pooled analyses of
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individual patient data from these and other obser-
vational studies—and, ultimately, randomized
controlled trials based on CMB burden—are
needed to fully assess the interaction between
CMBs and antithrombotic drugs (both antiplatelet
agents and anticoagulants) after IS and TIA. Nev-
ertheless, we have shown that with increasing
CMB burden, the risk of ICH increases more
steeply than that of IS in a cohort of IS and TIA
patients largely treated with antiplatelet medica-
tion. A high CMB burden (e.g., $5 CMBs) may
identify patients at similar or greater risk of ICH
than IS, with implications for antithrombotic
treatment and future randomized controlled trials.
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